Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005950 · ClinicalTrials.gov registry record · Phase 2
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT00005950: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00005950 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 111 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005950, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
Interventions
- DRUG nelarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2000-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005950
The ClinicalTrials.gov registry entry for NCT00005950 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nelarabine is the first listed.
NCT00005950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005950 about?
NCT00005950 is a clinical study titled "506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma". Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
What is the current status of trial NCT00005950?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2000-04.
What interventions are being tested in trial NCT00005950?
The interventions under investigation include: nelarabine (DRUG).
Who is sponsoring clinical trial NCT00005950?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.